Lisinopril as an efficient and safe hypotensive agent – cardiologist’s point of view Review article
Article Sidebar
Main Article Content
Abstract
Angiotensin converting enzyme inhibitors are one of the most popular drug classes used in both prophylaxis and treatment of the cardiovascular disease. Choice of a particular substance which in not only proven effective, but also characterized by safety, both as monotherapy and in combination with other drugs is a very important matter. Lisinopril is a long-acting derivative of enalaprilat – the active metabolite of enalapril, which in addition to proven antihypertensive efficacy has a good safety profile associated with a lack of hepatic metabolism, and thus less risk of interaction with some of the drugs used in cardiology. Lisinopril is highly efficient and safe also in combination with other hypertensive agents such as amlodipine or hydrochlorothiazide.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Kawamura M., Imanishi M., Matsushima Y. et al.: A comparison of lisinopril with enalapril by monitoring plasma angiotensin II levels in humans. Jpn J. Pharmacol. 1990; 54: 143-9.
3. Lisinopril. Mosby’s GenRx – The complete reference for generic and brand drugs. 9th edition. Mosby Inc., St. Louis (MI) 1999.
4. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15: 55-82.
5. Conway J., Coats A.J., Bird R.: Lisinopril and enalapril in hypertension: a comparative study using ambulatory monitoring. J. Hum. Hypertens. 1990; 4: 235-9.
6. Laher M.S., Natin D., Rao S.K. et al.: Lisinopril in elderly patients with hypertension. J. Cardiovasc. Pharmacol. 1987; 9(Suppl. 3): S69-71.
7. Gao Y., O’Caoimh R., Healy L. et al.: Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open 2013; 3pii: e002881.
8. Solfrizzi V., Scafato E., Frisardi V. et al.; Italian Longitudinal Study on Aging Working Group: Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age (Dordr) 2013; 35: 441-53.
9. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013; 31: 1281-1357.
10. Naidu M.U., Usha P.R., Rao T.R. et al.: Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension. Postgrad. Med. J. 2000; 76: 350-3.
11. Jalal S., Sofi F.A., Abass S.M. et al.: Effect of amlodipine and lisinopril on microalbuminuria in patients with essential hypertension: A prospective study. Indian J. Nephrol. 2010; 20: 15-20.
12. Pathé M.: Lisinopril-hydrochlorothiazide combination vs lisinopril for the treatment of hypertension. J. Hum. Hypertens. 1991; 5(Suppl. 2): 53-4.
13. Gerc V., Begović B., Vehabović M. et al.: Fixed combination lisinopril plus hydrochlorothiazide in the treatment of essential arterial hypertension: an opened, multi-centre, prospective clinical trial. Bosn. J. Basic Med. Sci. 2007; 7: 377-82.
14. Gerc V., Begović B., Vehabović M. et al. Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial. Bosn. J. Basic Med. Sci. 2008; 8: 214-9.